Lymphoma  >>  dexamethasone  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
NCT00000658: A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Completed
3
250
US
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
National Institute of Allergy and Infectious Diseases (NIAID), Schering-Plough
Lymphoma, Non-Hodgkin, HIV Infections
 
02/96
NCT00039910: Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Completed
3
240
US, Europe, RoW
(PN-152,243)/ PN-196,444
Pfizer
Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia
 
03/03
B1931006, NCT00562965 / 2007-000219-27: Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Checkmark P3 data - EHA
Jun 2012 - Jun 2012: P3 data - EHA
Terminated
3
29
US, Canada, Europe, RoW
inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
Pfizer, UCB Pharma
Lymphoma, Follicular
04/11
04/11
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells.

Ongoing
2/3
267
Europe, RoW
Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone
AB Science, AB Science
Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04]
 
 
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
Glo-BNHL, NCT05991388: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Not yet recruiting
2/3
210
NA
Odronextamab, REGN-1979, Loncastuximab tesirine, ADCT-402, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)
University of Birmingham, Cancer Research UK, Fight Kids Cancer, Regeneron Pharmaceuticals, ADC Therapeutics SA
B-cell Non Hodgkin Lymphoma
05/31
05/33

Download Options